ANDOVER, Mass., Feb. 20, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on February 18, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 40,089 shares of its common stock and an aggregate of 26,549 restricted stock units to 14 employees, each as a material inducement for each employee's entry into employment with TransMedics.
ANDOVER, Mass., Feb. 17, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences.
In this podcast, Motley Fool co-founder and CEO Tom Gardner talks about separating AI contenders from pretenders, his two favorite market indicators, and lessons from the dot-com bubble. Plus, Tom shares six stock ideas for the next five years.
TransMedics secures full FDA IDE approval for its OCS ENHANCE Heart trial, clearing a key hurdle and advancing its push to expand heart transplant use.
ANDOVER, Mass., Feb. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2025 after market close on Tuesday, February 24, 2026.
ANDOVER, Mass., Feb. 9, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of its Investigational Device Exemption (IDE) for the Next-Generation OCS ENHANCE Heart trial.
TransMedics: Italian NOP Program Reinforces Huge International Opportunity
Universal Beteiligungs und Servicegesellschaft mbH trimmed its position in shares of TransMedics Group, Inc. (NASDAQ: TMDX) by 85.8% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 65,345 shares of the company's stock after selling 396,232 shares during the quarter. Universal
Emerald Advisers LLC decreased its position in TransMedics Group, Inc. (NASDAQ: TMDX) by 11.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 387,588 shares of the company's stock after selling 51,741 shares during the quarter. TransMedics Group accounts for approximately 1.4%
Inspire Advisors LLC acquired a new position in TransMedics Group, Inc. (NASDAQ: TMDX) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 5,378 shares of the company's stock, valued at approximately $603,000. Other hedge funds have also recently made changes to
